# AbelZeta Inc.: Phase 2 study in Multiple Sclerosis, Primary Progressive Multiple Sclerosis (119 participants)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | AbelZeta Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy |
| NCT ID | NCT07825389 |
| Phase | Phase 2 |
| Status | not yet recruiting |
| Conditions | Multiple Sclerosis; Primary Progressive Multiple Sclerosis; Secondary Progress Multiple Sclerosis (SPMS); Primary Progressive Multiple Sclerosis (PPMS); MS; MS (Multiple Sclerosis) |
| Intervention types | drug |
| Target enrollment | 119 |
| Site countries | United States |
| Posted | 2026-09-17 |
| Planned start | 2027-02 |
| Event | Newly registered study |
| Event date | 2026-09-17 |

## Why this score
- Industry sponsor (buys outsourced services).
- Phase 2: multi-site, larger budget.
- 119 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07825389). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.